A detailed history of Gateway Investment Advisers LLC transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Gateway Investment Advisers LLC holds 4,449 shares of BMRN stock, worth $282,155. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,449
Previous 12,671 64.89%
Holding current value
$282,155
Previous $1.04 Million 70.09%
% of portfolio
0.0%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

SELL
$69.02 - $93.84 $567,482 - $771,552
-8,222 Reduced 64.89%
4,449 $312,000
Q2 2024

Jul 12, 2024

SELL
$74.43 - $92.22 $643,745 - $797,610
-8,649 Reduced 40.57%
12,671 $1.04 Million
Q1 2024

Apr 12, 2024

BUY
$83.81 - $99.0 $705,261 - $833,085
8,415 Added 65.21%
21,320 $1.86 Million
Q3 2023

Oct 19, 2023

SELL
$85.07 - $94.48 $13,866 - $15,400
-163 Reduced 1.25%
12,905 $1.14 Million
Q2 2023

Jul 13, 2023

SELL
$86.68 - $100.3 $2.1 Million - $2.43 Million
-24,215 Reduced 64.95%
13,068 $1.13 Million
Q1 2023

Apr 11, 2023

SELL
$87.74 - $117.27 $37,377 - $49,957
-426 Reduced 1.13%
37,283 $3.63 Million
Q4 2022

Jan 13, 2023

SELL
$80.93 - $108.63 $5,988 - $8,038
-74 Reduced 0.2%
37,709 $0
Q3 2022

Oct 07, 2022

BUY
$82.16 - $96.94 $1,643 - $1,938
20 Added 0.05%
37,783 $3.2 Million
Q2 2022

Jul 13, 2022

BUY
$71.48 - $86.85 $81,058 - $98,487
1,134 Added 3.1%
37,763 $3.13 Million
Q1 2022

Apr 14, 2022

BUY
$74.28 - $92.69 $1.96 Million - $2.45 Million
26,434 Added 259.28%
36,629 $2.82 Million
Q4 2021

Jan 14, 2022

BUY
$71.72 - $91.47 $14,128 - $18,019
197 Added 1.97%
10,195 $901,000
Q3 2021

Oct 22, 2021

SELL
$74.77 - $85.47 $4,261 - $4,871
-57 Reduced 0.57%
9,998 $773,000
Q2 2021

Jul 13, 2021

SELL
$75.51 - $84.79 $8,306 - $9,326
-110 Reduced 1.08%
10,055 $839,000
Q1 2021

Apr 14, 2021

SELL
$74.73 - $90.69 $12,405 - $15,054
-166 Reduced 1.61%
10,165 $768,000
Q4 2020

Jan 14, 2021

BUY
$72.61 - $90.2 $1,452 - $1,804
20 Added 0.19%
10,331 $906,000
Q3 2020

Oct 19, 2020

SELL
$71.87 - $131.03 $7,258 - $13,234
-101 Reduced 0.97%
10,311 $784,000
Q2 2020

Jul 15, 2020

SELL
$79.55 - $124.22 $2,704 - $4,223
-34 Reduced 0.33%
10,412 $1.28 Million
Q1 2020

Apr 13, 2020

SELL
$71.37 - $96.85 $232,737 - $315,827
-3,261 Reduced 23.79%
10,446 $883,000
Q4 2019

Jan 09, 2020

SELL
$64.27 - $86.37 $377,136 - $506,819
-5,868 Reduced 29.98%
13,707 $1.16 Million
Q3 2019

Oct 15, 2019

SELL
$67.4 - $85.11 $1,685 - $2,127
-25 Reduced 0.13%
19,575 $1.32 Million
Q2 2019

Jul 17, 2019

SELL
$80.35 - $93.9 $7,793 - $9,108
-97 Reduced 0.49%
19,600 $1.68 Million
Q1 2019

Apr 10, 2019

BUY
$84.2 - $98.62 $4,462 - $5,226
53 Added 0.27%
19,697 $1.75 Million
Q4 2018

Jan 14, 2019

BUY
$80.14 - $106.07 $462,568 - $612,236
5,772 Added 41.61%
19,644 $1.67 Million
Q3 2018

Oct 16, 2018

SELL
$93.92 - $105.72 $3,381 - $3,805
-36 Reduced 0.26%
13,872 $1.35 Million
Q2 2018

Jul 11, 2018

SELL
$76.01 - $99.03 $3,040 - $3,961
-40 Reduced 0.29%
13,908 $1.31 Million
Q1 2018

Apr 12, 2018

BUY
$77.67 - $92.63 $331,573 - $395,437
4,269 Added 44.11%
13,948 $1.13 Million
Q4 2017

Jan 17, 2018

BUY
$80.76 - $95.13 $781,676 - $920,763
9,679
9,679 $863,000

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $11.8B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Gateway Investment Advisers LLC Portfolio

Follow Gateway Investment Advisers LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gateway Investment Advisers LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gateway Investment Advisers LLC with notifications on news.